Safety and efficacy of FGF21 analogs in nonalcoholic steatohepatitis: a meta-analysis of randomized clinical trials
Milene Vitória Sampaio Sobral1*, Hilária Saugo Faria2*, Lucas Cael Azevedo Ramos Bendaham3, Barbara Bombassaro Masiero4, Celine Almeida Gouvêa5, Giovana de Souza Faria6, Maria Clara Morgado Santos7, Clara de Andrade Pontual Peres8, Lídia Santos Oliveira9, Eduardo Buzatti Souto10, M.D.
1University of Western São Paulo, Presidente Prudente, Brazil
2Federal University of Santa Maria, Santa Maria, Brazil
3Federal University of Roraima, Boa Vista, Brazil
4Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil
5National University of La Plata, La Plata, Argentina
6University Center of Barão de Mauá, Ribeirão Preto, Brazil
7University Salvador, Salvador, Brazil
8University of Pernambuco, Recife, Brazil
9University São Judas Tadeu, Cubatão, Brazil
10Division of Gastroenterology, Department of Internal Medicine, University Hospital of Santa Maria, Santa Maria, Brazil
*Contributed equally to this manuscript
Short title: FGF21 analogs in patients with NASH
Word count: 2.594
Address for correspondence
Eduardo Buzatti Souto, M.D.
Address: Coronel Niederauer 621/802, Camobi, Santa Maria, Brazil
Office number: Avenue Roraima, 1000 - 22 - Camobi, Santa Maria - RS, 97105-900
Email: eduardo.souto@ufsm.br
Disclosures: All authors report no relationships that could be construed as a conflict of interest. All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.